Company intelligence / Profile preview

Vitalli Bio

Oakland, California, United States

Ownership: Private
Development stage: Other

Overview

Vitalli Bio was formed in 2023 by Aditum Bio to develop VIT-801 (formerly DWP213388), an oral dual BTK/ITK inhibitor for autoimmune and other immunological disorders; the asset was anticipated to enter Phase 1 in 2023 based on an FDA-cleared IND, but in 2024 Vitalli terminated its $477M license for DWP213388 with Daewoong while retaining an option to license two additional dual inhibitors, and there are no public Phase 1 efficacy results yet.[1][2][3][4][7]

Therapeutic areas: Immunology
Modalities: Small molecule
Industry: Biotech

Partnerships

Daewoong Pharmaceutical

Beyond the preview

Go deeper on Vitalli Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitalli Bio.

Explore the full profile